CHD
MCID: CRN018
MIFTS: 74

Coronary Artery Anomaly (CHD)

Categories: Blood diseases, Cardiovascular diseases, Genetic diseases

Aliases & Classifications for Coronary Artery Anomaly

MalaCards integrated aliases for Coronary Artery Anomaly:

Name: Coronary Artery Anomaly 39 12 15
Coronary Artery Disease 39 12 38 30 13 56 6 44 45 15 17 74
Myocardial Ischemia 45 17 74
Coronary Artery Disease, Susceptibility to 13 6
Coronary Arteriosclerosis 12 74
Coronary Heart Disease 12 74
Coronary Disease 12 45
Congenital Anomaly of Coronary Artery 12
Coronary Artery Anomaly, Congenital 12
Coronary Artery Abnormality 12
Coronary Syndrome 15
Chd 12

Classifications:



Summaries for Coronary Artery Anomaly

MedlinePlus : 44 Coronary artery disease (CAD) is the most common type of heart disease. It is the leading cause of death in the United States in both men and women. CAD happens when the arteries that supply blood to heart muscle become hardened and narrowed. This is due to the buildup of cholesterol and other material, called plaque, on their inner walls. This buildup is called atherosclerosis. As it grows, less blood can flow through the arteries. As a result, the heart muscle can't get the blood or oxygen it needs. This can lead to chest pain (angina) or a heart attack. Most heart attacks happen when a blood clot suddenly cuts off the hearts' blood supply, causing permanent heart damage. Over time, CAD can also weaken the heart muscle and contribute to heart failure and arrhythmias. Heart failure means the heart can't pump blood well to the rest of the body. Arrhythmias are changes in the normal beating rhythm of the heart. NIH: National Heart, Lung, and Blood Institute

MalaCards based summary : Coronary Artery Anomaly, also known as coronary artery disease, is related to coronary heart disease 1 and intermediate coronary syndrome, and has symptoms including tremor, angina pectoris and edema. An important gene associated with Coronary Artery Anomaly is PON1 (Paraoxonase 1), and among its related pathways/superpathways are cGMP-PKG signaling pathway and Wnt signaling pathway. The drugs Aspirin and AT-101 have been mentioned in the context of this disorder. Affiliated tissues include heart, endothelial and testes, and related phenotypes are cardiovascular system and homeostasis/metabolism

Related Diseases for Coronary Artery Anomaly

Diseases in the Coronary Artery Anomaly family:

Coronary Artery Disease, Autosomal Dominant, 1 Coronary Artery Disease, Autosomal Dominant 2

Diseases related to Coronary Artery Anomaly via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 775)
# Related Disease Score Top Affiliating Genes
1 coronary heart disease 1 34.3 ACE ADRB1 APOA1 APOB CRP NOS3
2 intermediate coronary syndrome 33.8 ACE CRP MB PIK3C2A PLAT TNNI3
3 hypercholesterolemia, familial 32.6 ACE APOA1 APOB CRP NOS3 PON1
4 diabetes mellitus 31.2 ACE APOA1 APOB CRP EDN1 IRS1
5 mitral valve insufficiency 31.2 ACE NPPA NPPB
6 atrial standstill 1 31.1 ACE ADRB1 NPPB TNNI3
7 end stage renal failure 31.1 ACE APOB CRP
8 lipid metabolism disorder 31.1 ACE APOA1 APOB CRP SERPINE1
9 orthostatic intolerance 31.0 ADRB1 EDN1 NOS3
10 systolic heart failure 31.0 ACE ADRB1 CRP EDN1 NPPB
11 glucose intolerance 31.0 APOB CRP IRS1
12 sleep apnea 31.0 ACE CRP EDN1 NOS3 NPPB
13 diabetes mellitus, noninsulin-dependent 31.0 ACE APOA1 APOB CRP EDN1 IRS1
14 congestive heart failure 31.0 ACE ADRB1 EDN1 KNG1 NPPA NPPB
15 impotence 31.0 EDN1 KNG1 NOS3
16 tetralogy of fallot 30.9 CRP EDN1 GJA1 NPPA NPPB
17 cerebrovascular disease 30.9 ACE APOA1 APOB CRP PLAT PON1
18 carotid artery disease 30.9 ACE APOA1 APOB CRP
19 cardiogenic shock 30.9 NPPB PIK3C2A PLAT
20 atrial fibrillation 30.8 ACE ADRB1 CRP GJA1 NPPA NPPB
21 kidney disease 30.8 ACE CRP EDN1 NOS3 NPPA NPPB
22 peripheral artery disease 30.8 ACE APOB CRP NOS3
23 ischemic heart disease 30.7 ACE APOA1 APOB CRP NOS3 NPPB
24 limb ischemia 30.7 ACE EDN1 NOS3 TNNI3
25 mitral valve disease 30.7 ACE NOS3 NPPA
26 sexual disorder 30.7 ACE EDN1 NOS3
27 chronic kidney failure 30.7 ACE APOB CRP EDN1 NOS3 NPPA
28 central serous chorioretinopathy 30.6 PLAT SERPINE1
29 myocarditis 30.6 MB NPPB TNNI3
30 inferior myocardial infarction 30.6 NPPB PIK3C2A PLAT TET1
31 pulmonary edema 30.6 ACE CRP EDN1 NOS3 NPPA NPPB
32 systemic scleroderma 30.6 ACE CRP EDN1
33 gas gangrene 30.6 MB PIK3C2A TNNI3
34 peripheral vascular disease 30.6 ACE APOA1 APOB CRP PLAT SERPINE1
35 arteriosclerosis 30.5 ACE APOA1 APOB CRP EDN1 PON1
36 intermittent claudication 30.5 ACE CRP SERPINE1
37 cardiac arrest 30.5 ACE NPPB PIK3C2A
38 pulmonary hypertension 30.5 ACE EDN1 NOS3 NPPA NPPB PLAT
39 aortic valve insufficiency 30.5 ACE NPPB PON1
40 stroke, ischemic 30.5 ACE APOB CRP NOS3 PLAT PON1
41 coronary stenosis 30.5 ACE APOA1 APOB CRP NPPB PIK3C2A
42 microvascular complications of diabetes 5 30.5 ACE NOS3 PON1 SERPINE1
43 pulmonary embolism 30.5 CRP FABP3 NPPB PLAT SERPINE1 TNNI3
44 renovascular hypertension 30.5 ACE EDN1 NOS3 NPPA
45 diastolic heart failure 30.5 ACE NOS3 NPPA NPPB
46 aortic coarctation 30.4 ACE ADRB1 EDN1 NOS3
47 left bundle branch hemiblock 30.4 ACE NPPB TNNI3
48 vascular disease 30.4 ACE APOA1 APOB CRP EDN1 KNG1
49 generalized atherosclerosis 30.3 ACE CRP
50 coronary artery vasospasm 30.3 EDN1 NOS3 PIK3C2A

Graphical network of the top 20 diseases related to Coronary Artery Anomaly:



Diseases related to Coronary Artery Anomaly

Symptoms & Phenotypes for Coronary Artery Anomaly

UMLS symptoms related to Coronary Artery Anomaly:


tremor, angina pectoris, edema, chest pain, equilibration disorder, other and unspecified angina pectoris, substernal pain

MGI Mouse Phenotypes related to Coronary Artery Anomaly:

47 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.41 ACE ADRB1 APOA1 APOB CRP EDN1
2 homeostasis/metabolism MP:0005376 10.25 ACE ADRB1 APOA1 APOB CRP EDN1
3 growth/size/body region MP:0005378 10.22 ACE ADRB1 APOB EDN1 GJA1 IRS1
4 cellular MP:0005384 10.2 APOA1 APOB FABP3 GJA1 IRS1 MB
5 endocrine/exocrine gland MP:0005379 10.09 ACE ADRB1 APOA1 EDN1 GJA1 IRS1
6 hematopoietic system MP:0005397 10.07 ACE GJA1 IRS1 MB NOS3 NPPA
7 adipose tissue MP:0005375 10.04 ACE ADRB1 FABP3 IRS1 NOS3 PIK3C2A
8 mortality/aging MP:0010768 10 ACE ADRB1 APOB EDN1 FABP3 GJA1
9 liver/biliary system MP:0005370 9.8 ACE APOA1 APOB FABP3 IRS1 NOS3
10 muscle MP:0005369 9.7 ADRB1 APOB EDN1 FABP3 GJA1 IRS1
11 respiratory system MP:0005388 9.17 GJA1 MB NOS3 PLAT SERPINE1 TET1

Drugs & Therapeutics for Coronary Artery Anomaly

Drugs for Coronary Artery Anomaly (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1136)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aspirin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 50-78-2 2244
2
AT-101 Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 90141-22-3, 652-67-5 12597
3
Atorvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 134523-00-5 60823
4
Nitric Oxide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 10102-43-9 145068
5
Clopidogrel Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 120202-66-6, 113665-84-2 60606
6
Isosorbide Dinitrate Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 87-33-2 6883
7
Metoprolol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 37350-58-6, 51384-51-1 4171
8
Trimetazidine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 5011-34-7
9
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
10
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53123-88-9 46835353 6436030 5284616
11
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 159351-69-6 6442177 70789204
12
Ticagrelor Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 274693-27-5 9871419
13
Cilostazol Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 73963-72-1 2754
14
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9005-49-6 772 46507594
15
Tirofiban Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 144494-65-5 60947
16 Nutmeg Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17
Chlorhexidine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 55-56-1 2713 9552079
18
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 68521-88-0, 11128-99-7, 4474-91-3 172198 65143
19
Olmesartan Approved, Investigational Phase 4,Phase 2 144689-24-7, 144689-63-4 130881 158781
20
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 79902-63-9 54454
21
Insulin glargine Approved Phase 4,Phase 3 160337-95-1
22
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 657-24-9 14219 4091
23
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7440-66-6 32051
24
Amlodipine Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 88150-42-9 2162
25
Rivaroxaban Approved Phase 4,Phase 3,Phase 2 366789-02-8
26
Warfarin Approved Phase 4,Phase 2,Phase 3,Not Applicable 81-81-2 6691 54678486
27
Ranolazine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 142387-99-3, 95635-55-5 56959
28
Acarbose Approved, Investigational Phase 4,Phase 3,Not Applicable 56180-94-0 441184
29
Chromium Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 7440-47-3 27668
30
Cobalt Approved, Experimental Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 7440-48-4 104729
31
Bivalirudin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 128270-60-0 16129704
32
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
33
Rosiglitazone Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 122320-73-4 77999
34
Pitavastatin Approved Phase 4,Phase 3,Not Applicable 147526-32-7, 147511-69-1 6366718 5282452
35
Lovastatin Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 75330-75-5 53232
36
Ezetimibe Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 163222-33-1 150311
37
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 111025-46-8 4829
38
Tocopherol Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 1406-66-2 14986
39
Regadenoson Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 313348-27-5 219024
40
Dipyridamole Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-32-2 3108
41
Adenosine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-61-7 60961
42
Thrombin Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable
43
Vorapaxar Approved Phase 4,Phase 3,Phase 2,Phase 1 618385-01-6
44
Enoxaparin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9005-49-6 772
45
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 3 73590-58-6 4594
46
Pantoprazole Approved Phase 4,Phase 3,Phase 1,Not Applicable 102625-70-7 4679
47
Fenoldopam Approved Phase 4 67227-57-0, 67227-56-9 3341
48
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 62-31-7, 51-61-6 681
49
Coal tar Approved Phase 4,Phase 1,Phase 2,Not Applicable 8007-45-2
50
Eptifibatide Approved, Investigational Phase 4,Phase 3,Phase 2 188627-80-7 123610

Interventional clinical trials:

(show top 50) (show all 8214)
# Name Status NCT ID Phase Drugs
1 Curative Effect Evaluation of Danlou Tablet on Coronary Artery Disease Not Amenable to Revascularization Unknown status NCT03072082 Phase 4 Danlou Tablet;DanLou Tablet placebo;Aspirin Enteric-coated Tablets;Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet;Atorvastatin calcium;Isosorbide Mononitrate Tab 20 MG;Metoprolol Tartrate Tab 25 MG;Trimetazidine Dihydrochloride Tablets
2 Curative Effect Evaluation of Shexiang Baoxin Pill on Coronary Artery Disease Not Amenable to Revascularization Unknown status NCT03072121 Phase 4 Shexiang Baoxin pill;SBP placebo;Aspirin Enteric-coated Tablets;Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet;Atorvastatin Calcium;Isosorbide Mononitrate Tab 20 MG;Metoprolol Tartrate Tab 25 MG;Trimetazidine Dihydrochloride Tablets
3 The Beneficial Role of Percutaneous Coronary Intervention Over Optimal Medical Therapy in Elderly Patients With Coronary Artery Disease Unknown status NCT01508663 Phase 4 ARB, CCB, ACE-inhibitor, statin, Nitrate, Antiplate etc.
4 Safety and Efficacy of Low-dose Ticagrelor in Chinese Patients With Stable Coronary Artery Disease Unknown status NCT02514642 Phase 4 low-dose ticagrelor;Clopidogrel
5 A Trial to Evaluate Efficacy of Heart-protecting Musk Pill Unknown status NCT01897805 Phase 4 Heart-protecting Musk Pill;Placebo
6 Effect of Cilostazol on Endothelial Progenitor Cells and Endothelial Function in Coronary Artery Disease Unknown status NCT02174939 Phase 4 Cilostazol;Dummy Placebo
7 Efficacy and Safety of Different Dose of Tirofiban in Interventional Treatment of Complex Coronary Artery Disease Unknown status NCT02294994 Phase 4 tirofiban
8 The Association Between Very Small Embryonic-like Stem Cells and the Prognosis of Coronary Artery Disease Patients Unknown status NCT01633359 Phase 4 Intensive statin;Routine statin
9 Firebird 2 Versus Excel Sirolimus-eluting Stent in Treating Real-world Patients With Coronary Artery Disease Unknown status NCT01373632 Phase 4
10 Efficacy Study of Olmesartan Medoxomil on Coronary Atherosclerosis and Epicardial Adipose Tissue(EAT) Unknown status NCT02360956 Phase 4 Olmesartan medoxomil tablets;Antihypertensive medication (per doctor suggestion)
11 Pharmacodynamic Comparison of Rosuvastatin Versus Atorvastatin on Platelet Reactivity in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With New P2Y12 Inhibitors (Trial gRANADa) Unknown status NCT02030054 Phase 4 Atorvastatin;Rosuvastatin
12 Endothelial Dysfunction in Subjects With History of Premature Coronary Artery Disease Unknown status NCT00917527 Phase 4 Atorvastatin
13 Low-dose Statins and Nutraceuticals in High-intensity Statin-intolerant Patients Unknown status NCT02001883 Phase 4 Association low-dose statin and nutraceuticals
14 Comparison of TIcagrelor and Clopidogrel in Patients With Coronary Artery diseaSe and Type 2 Diabetes Mellitus (TICS-DM) Unknown status NCT02457130 Phase 4 Ticagrelor;Clopidogrel
15 The ImPact of Trimetazidine on MicrOcirculation After Stenting for Stable Coronary Artery Disease Unknown status NCT02107144 Phase 4 trimetazidine
16 Can Insulin Glargine Improve Myocardial Function in Patients With T2D and Coronary Artery Disease (CAD) Unknown status NCT01035528 Phase 4 insulin glargine;metformin
17 Cerebral Artery Stenosis, Coronary Artery Disease and Arrhythmia Unknown status NCT00247533 Phase 4
18 Rosuvastatin Effect on Reducing Coronary Atherosclerosis Plaques Volume Unknown status NCT01382277 Phase 4 Rosuvastatin
19 Xience/Promus for Long Coronary Lesion Registry Unknown status NCT01147237 Phase 4
20 A Prospective Multicenter Trial Evaluating Helios Biodegradable Polymer SES Safety and Effectiveness in CAD Treatment Unknown status NCT01880879 Phase 4
21 Comparison of Biomatrix and Orsiro Drug Eluting Stent Unknown status NCT02299011 Phase 4 Biomatrix drug eluting stent
22 The Prediction of Extent and Risk Profile of Coronary Atherosclerosis and Their Changes During Lipid-lowering Therapy Based on Non-invasive Techniques Unknown status NCT01773512 Phase 4 Rosuvastatin
23 Study to Investigate the Effect of Heart Rate Reduction With Ivabradine on Vascular Elastic Properties and Endothelial Function in Patients With Stable Coronary Heart Disease Unknown status NCT01768585 Phase 4 Ivabradine;Placebo
24 Pharmacodynamic Effects of Atorvastatin vs. Rosuvastatin on Platelet Reactivity Unknown status NCT01567774 Phase 4 Atorvastatin;Rosuvastatin
25 Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention Unknown status NCT02334254 Phase 4 rivaroxaban and ticagrel therapy;triple antithrombotic regimen with warfarin, asipirin and clopidogrel
26 Pharmacodynamic Effects of Ranolazine Versus Amlodipine on Platelet Reactivity Unknown status NCT01490255 Phase 4 Ranolazine;Amlodipine
27 Danshen Dropping Pill for Coronary Heart Disease Heart and Artery Structure and Function Unknown status NCT01825759 Phase 4 danshen dripping pill
28 Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study Unknown status NCT02642419 Phase 4 Rivaroxaban and single antiplatelet drug (aspirin, clopidogrel or prasugrel);Rivaroxaban
29 Impact of Acarbose on Abnormal Glucose Regulation in Patients With Coronary Artery Disease (AAA Trial) Unknown status NCT00858676 Phase 4 acarbose
30 Safety and Effectiveness of the Coronary Momo Stent Unknown status NCT01535625 Phase 4
31 Study Effects of Ginkgo Biloba Extract on Endothelial Cell Function and Genetic Effects on the Response to Ginkgo Biloba Extract in Diabetic Patients With Stable Coronary Artery Disease Unknown status NCT01038050 Phase 4 Ginkgo Biloba Extract (GBE)
32 Bivalirudin in Stable Ischemic Heart Disease Patients Undergoing PCI Unknown status NCT02787317 Phase 4 bivalirudin;Heparin
33 Ranolazine, Ethnicity and the Metabolic Syndrome Unknown status NCT01304095 Phase 4 Ranolazine
34 Assessment of Surface Coverage of Two Types of DES in Diabetes Mellitus and Non- Diabetes Mellitus Unknown status NCT01023919 Phase 4
35 Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy With Ticagrelor Unknown status NCT01869309 Phase 4 Prasugrel;Ticagrelor
36 Rosiglitazone Therapy In The Prevention Of Coronary Artery Disease In Patients With Impaired Glucose Tolerance Unknown status NCT00733174 Phase 4 Rosiglitazone;Placebo
37 PharmacOdynamic compaRison of piTavastatin Versus atOrvastatin on Platelet Reactivity Unknown status NCT01648829 Phase 4 Atorvastatin;Pitavastatin
38 The Effect of Tongguan Capsule for MicroRNA Profiles in Coronary Heart Disease Patients Unknown status NCT02850627 Phase 4 Tongguan capsule;placebo capsule
39 Multivessel Stenting Versus Staged Revascularization With Zotarolimus-eluting Stent for STEMI Unknown status NCT01781715 Phase 4
40 Cholesterol-lowering Effects of nutraceuticaLs Versus Ezetimibe in Statin-intolerant Patients Unknown status NCT01807078 Phase 4 Ezetimibe
41 Ranolazine for Improving Symptoms of Palpitations Unknown status NCT01495520 Phase 4 Ranolazine;Placebo
42 Treatment of Coronary Atherosclerosis by Insulin Sensitizers in Insulin-Resistant Patients Unknown status NCT00155350 Phase 4 pioglitazone
43 Clinical Study of Combination Therapy for Angina of Coronary Heart Disease With Aspirin and Salvianolate Injection Unknown status NCT02694848 Phase 4 Salvianolate injection;Aspirin
44 Prospective Multicenter Registry of Hybrid Coronary Artery Revascularization Combined With Surgical Bypass and Percutaneous Coronary Intervention Using Everolimus Eluting Metallic Stents Unknown status NCT02894255 Phase 4
45 Comparison of Biolimus-eluting Biodegradable Polymer, Everolimus-eluting and Sirolimus-eluting Coronary Stents Unknown status NCT01268371 Phase 4
46 Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - SAfety & EffectiveneSS of Drug-ElUting Stents & Anti-platelet REgimen Unknown status NCT01267734 Phase 4 Triple anti-platelet therapy (TAT);Double-dose clopidogrel anti-platelet therapy (DDAT)
47 Periodontal Therapy in Coronary Artery Patients Unknown status NCT01609725 Phase 4
48 A Registry To Evaluate Safety And Effectiveness Of Everolimus Drug Eluting Stent For Coronary Revascularization Unknown status NCT01157455 Phase 4 Aspirin;Clopidogrel;Heparin or Bivalirudin
49 Plasma and Platelet microRNAs in Clopidogrel Low Response Patients Unknown status NCT02447809 Phase 4 Clopidogrel;acetylsalicylic acid (ASA)
50 Italian Diffuse/Multivessel Disease ABSORB Prospective Registry: IT-Disappears Unknown status NCT02004730 Phase 4

Search NIH Clinical Center for Coronary Artery Anomaly

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Coronary Artery Anomaly cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: coronary artery disease

Genetic Tests for Coronary Artery Anomaly

Genetic tests related to Coronary Artery Anomaly:

# Genetic test Affiliating Genes
1 Coronary Artery Disease 30

Anatomical Context for Coronary Artery Anomaly

MalaCards organs/tissues related to Coronary Artery Anomaly:

42
Heart, Endothelial, Testes, Bone, Kidney, Bone Marrow, Liver

Publications for Coronary Artery Anomaly

Articles related to Coronary Artery Anomaly:

(show top 50) (show all 7617)
# Title Authors Year
1
Glycaemic variability is associated with severity of coronary artery disease in patients with poorly controlled type 2 diabetes and acute myocardial infarction. ( 30763700 )
2019
2
Treatment of Coronary Artery Disease and Acute Myocardial Infarction in Hospitals With and Without On-Site Coronary Artery Bypass Graft Surgery. ( 30616362 )
2019
3
Urinary excretion of homocysteine thiolactone and the risk of acute myocardial infarction in coronary artery disease patients: the WENBIT trial. ( 30193001 )
2019
4
Age-dependent association of pulse wave velocity with coronary artery disease and myocardial aging in high-risk patients. ( 30676495 )
2019
5
Coexistence of cardiac amyloidosis with coronary artery disease and the challenges in medical management. ( 30788761 )
2019
6
3D-speckle tracking echocardiography for assessment of coronary artery disease severity in stable angina pectoris. ( 30515893 )
2019
7
Effect of Sexual Rehabilitation Program on Anxiety, Stress, Depression and Sexual Function among Men with Coronary Artery Disease. ( 30912471 )
2019
8
The Effect of Two Methods of Relaxation and Prayer Therapy on Anxiety and Hope in Patients with Coronary Artery Disease: A Quasi-Experimental Study. ( 30820220 )
2019
9
The effect of Xinkeshu tablets on depression and anxiety symptoms in patients with coronary artery disease: Results from a double-blind, randomized, placebo-controlled study. ( 30784924 )
2019
10
Rheumatoid arthritis patients have higher prevalence and burden of asymptomatic coronary artery disease assessed by coronary computed tomography: A systematic literature review and meta-analysis. ( 30826172 )
2019
11
Subclinical coronary artery disease in recent-onset of rheumatoid arthritis. ( 30723868 )
2019
12
Associations between statins and coronary artery disease and stroke risks in patients with asthma-chronic obstructive pulmonary disease overlap syndrome: A time-dependent regression study. ( 30782562 )
2019
13
Thromboembolic Risk of Imaging-Confirmed Coronary Artery Disease Without Myocardial Infarction in Patients With Nonvalvular Atrial Fibrillation. ( 30709601 )
2019
14
Cardiovascular outcomes among elderly patients with heart failure and coronary artery disease and without atrial fibrillation: a retrospective cohort study. ( 30646855 )
2019
15
Open-Label Randomized Trial Comparing Oral Anticoagulation With and Without Single Antiplatelet Therapy in Patients With Atrial Fibrillation and Stable Coronary Artery Disease Beyond 1 Year After Coronary Stent Implantation. ( 30586700 )
2019
16
Aspirin on Top of Anticoagulation in Patients With Concomitant Stable Coronary Artery Disease and Atrial Fibrillation. ( 30586780 )
2019
17
Progression of carotid artery disease could stratify a risk of coronary artery disease patients with type 2 diabetes. ( 30544223 )
2019
18
Association of PON1 gene promoter DNA methylation with the risk of Clopidogrel resistance in patients with coronary artery disease. ( 30891852 )
2019
19
Regional 18F-FDG uptake indicates coronary artery anomaly in a middle-aged patient with no atherosclerosis risk. ( 30820815 )
2019
20
miR-196a2 (rs11614913) polymorphism is associated with coronary artery disease, but not with in-stent coronary restenosis. ( 30560371 )
2019
21
Somatic and sociodemographic predictors of depression outcome among depressed patients with coronary artery disease - a secondary analysis of the SPIRR-CAD study. ( 30717711 )
2019
22
Is Obstructive Sleep Apnea a Risk Factor for Depression in Coronary Artery Disease? ( 30592447 )
2019
23
The association of obesity and coronary artery disease genes with response to SSRIs treatment in major depression. ( 30610379 )
2019
24
Changes in pentraxin-3 level and its interaction with metabolic indices in patients with coronary artery disease and type 2 diabetes mellitus. ( 30903769 )
2019
25
Everolimus-eluting bioresorbable scaffolds for treatment of coronary artery disease in patients with diabetes mellitus: the midterm follow-up of the prospective ABSORB DM Benelux study. ( 30851731 )
2019
26
Relationships between blood pressure lowering therapy and cardiovascular events in hypertensive patients with coronary artery disease and type 2 diabetes mellitus: The HIJ-CREATE sub-study. ( 30735770 )
2019
27
Serum protein signature of coronary artery disease in type 2 diabetes mellitus. ( 30674322 )
2019
28
Thrombotic/Thrombolytic Balance as a Cardiac Treatment Determinant in Patients With Diabetes Mellitus and Coronary Artery Disease. ( 30646801 )
2019
29
Influence of chronic kidney disease on coronary plaque components in coronary artery disease patients with both diabetes mellitus and hypertension. ( 30607540 )
2019
30
Perioperative Management of Antiplatelet Therapy in Patients With History of Coronary Artery Disease Undergoing Surgery for Esophageal Cancer: A Single-center Experience. ( 30804150 )
2019
31
Impact of Non-Alcoholic Fatty Liver Disease on Cardiovascular Outcomes in Patients With Stable Coronary Artery Disease: A Matched Case-Control Study. ( 30829918 )
2019
32
Where are we with coronary artery disease for the cyanotic patient with congenital heart disease? ( 30665555 )
2019
33
Marked multi-distribution myocardial ischemia in a patient with hypertrophic cardiomyopathy and no obstructive coronary artery disease. ( 30719657 )
2019
34
Implications of Hyperuricemia in Severe Coronary Artery Disease. ( 30527777 )
2019
35
Sex-Specific Association Between Coronary Artery Disease Severity and Myocardial Ischemia Induced by Mental Stress. ( 30571661 )
2019
36
Impact of regional functional ischemia on global coronary flow reserve in patients with stable coronary artery disease. ( 30583990 )
2019
37
The role of sphingosine 1 phosphate in coronary artery disease and ischemia reperfusion injury. ( 30341893 )
2019
38
Characteristics of coronary artery disease in chronic kidney disease. ( 30830548 )
2019
39
Comparison of coronary artery bypass grafting and drug-eluting stents in patients with left main coronary artery disease and chronic kidney disease: A systematic review and meta-analysis. ( 30842042 )
2019
40
Prognostic Utility of Oxygen-Sensitive Cardiac Magnetic Resonance Imaging in Diabetic and Nondiabetic Chronic Kidney Disease Patients With No Known Coronary Artery Disease. ( 30772234 )
2019
41
Association of lipoprotein(a) and coronary artery disease in 1003 patients with stage 3-5 chronic kidney disease undergoing coronary angiography. ( 30585793 )
2019
42
Contemporary Diagnosis and Management of Patients With Myocardial Infarction in the Absence of Obstructive Coronary Artery Disease: A Scientific Statement From the American Heart Association. ( 30913893 )
2019
43
Predictive value of global and territorial longitudinal strain imaging in detecting significant coronary artery disease in patients with myocardial infarction without persistent ST-segment elevation. ( 30803009 )
2019
44
Optimal cardiac strategy based on the history of myocardial infarction in type 2 diabetic patients with coronary artery disease. ( 30837527 )
2019
45
Levodopa-induced myocardial infarction in a patient with Parkinson's disease and severe coronary artery disease. ( 30838990 )
2019
46
Gated single-photon emission computed tomography myocardial perfusion imaging is superior to computed tomography attenuation correction in discriminating myocardial infarction from attenuation artifacts in men and right coronary artery disease. ( 30855541 )
2019
47
Pharmacokinetic-pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patients. ( 30414387 )
2019
48
Management of established coronary artery disease in aircrew without myocardial infarction or revascularisation. ( 30425083 )
2019
49
Management of established coronary artery disease in aircrew with previous myocardial infarction or revascularisation. ( 30425084 )
2019
50
Seasonal and circadian patterns of myocardial infarction by coronary artery disease status and sex in the ACTION Registry-GWTG. ( 30217419 )
2019

Variations for Coronary Artery Anomaly

ClinVar genetic disease variations for Coronary Artery Anomaly:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 TERT TERT, -1327T-C single nucleotide variant Uncertain significance
2 PON1 NM_000446.6(PON1): c.575A> G (p.Gln192Arg) single nucleotide variant risk factor rs662 GRCh37 Chromosome 7, 94937446: 94937446
3 PON1 NM_000446.6(PON1): c.575A> G (p.Gln192Arg) single nucleotide variant risk factor rs662 GRCh38 Chromosome 7, 95308134: 95308134
4 PON1 NM_000446.6(PON1): c.163T> A (p.Leu55Met) single nucleotide variant risk factor rs854560 GRCh37 Chromosome 7, 94946084: 94946084
5 PON1 NM_000446.6(PON1): c.163T> A (p.Leu55Met) single nucleotide variant risk factor rs854560 GRCh38 Chromosome 7, 95316772: 95316772
6 IRS1 NM_005544.2(IRS1): c.2911G> A (p.Gly971Arg) single nucleotide variant risk factor rs1801278 GRCh37 Chromosome 2, 227660544: 227660544
7 IRS1 NM_005544.2(IRS1): c.2911G> A (p.Gly971Arg) single nucleotide variant risk factor rs1801278 GRCh38 Chromosome 2, 226795828: 226795828

Copy number variations for Coronary Artery Anomaly from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13312 1 1 117600000 Copy number Coronary Disease
2 207742 6 160872504 161007397 Copy number LPA Coronary Disease
3 207743 6 160872504 161007397 Copy number LPA Coronary Disease
4 250037 9 19900000 32800000 Copy number Coronary Disease

Expression for Coronary Artery Anomaly

Search GEO for disease gene expression data for Coronary Artery Anomaly.

Pathways for Coronary Artery Anomaly

Pathways related to Coronary Artery Anomaly according to KEGG:

38
# Name Kegg Source Accession
1 cGMP-PKG signaling pathway hsa04022
2 Wnt signaling pathway hsa04310

GO Terms for Coronary Artery Anomaly

Cellular components related to Coronary Artery Anomaly according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.85 ACE APOA1 APOB FABP3 KNG1 MB
2 early endosome GO:0005769 9.71 ADRB1 APOA1 APOB GJA1
3 extracellular region GO:0005576 9.7 ACE APOA1 APOB CRP EDN1 KNG1
4 collagen-containing extracellular matrix GO:0062023 9.65 APOA1 KNG1 NPPA PLAT SERPINE1
5 contractile fiber GO:0043292 9.49 GJA1 TNNI3
6 endocytic vesicle lumen GO:0071682 9.48 APOA1 APOB
7 low-density lipoprotein particle GO:0034362 9.46 APOA1 APOB
8 chylomicron GO:0042627 9.43 APOA1 APOB
9 extracellular space GO:0005615 9.4 ACE APOA1 APOB CRP EDN1 FABP3
10 spherical high-density lipoprotein particle GO:0034366 9.37 APOA1 PON1
11 intermediate-density lipoprotein particle GO:0034363 9.32 APOA1 APOB

Biological processes related to Coronary Artery Anomaly according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 heart development GO:0007507 9.88 EDN1 GJA1 MB TNNI3
2 cellular protein metabolic process GO:0044267 9.83 APOA1 APOB KNG1 NPPA
3 in utero embryonic development GO:0001701 9.8 APOB EDN1 GJA1 NOS3
4 cholesterol homeostasis GO:0042632 9.79 APOA1 APOB FABP3
5 cholesterol metabolic process GO:0008203 9.78 APOA1 APOB PON1
6 response to insulin GO:0032868 9.73 FABP3 IRS1 NPPA
7 response to hypoxia GO:0001666 9.71 EDN1 MB NPPA PLAT
8 response to lipopolysaccharide GO:0032496 9.67 APOB EDN1 GJA1 NOS3
9 response to muscle stretch GO:0035994 9.64 EDN1 NPPA
10 heart contraction GO:0060047 9.64 ACE TNNI3
11 negative regulation of wound healing GO:0061045 9.63 GJA1 SERPINE1
12 positive regulation of renal sodium excretion GO:0035815 9.63 EDN1 NPPB
13 positive regulation of urine volume GO:0035810 9.62 EDN1 NPPB
14 regulation of blood vessel diameter GO:0097746 9.62 ACE NPPB
15 cGMP biosynthetic process GO:0006182 9.6 NPPA NPPB
16 receptor guanylyl cyclase signaling pathway GO:0007168 9.59 NPPA NPPB
17 chylomicron assembly GO:0034378 9.58 APOA1 APOB
18 phospholipid homeostasis GO:0055091 9.57 APOA1 FABP3
19 body fluid secretion GO:0007589 9.55 EDN1 NPPB
20 response to fluid shear stress GO:0034405 9.54 GJA1 NOS3
21 chylomicron remodeling GO:0034371 9.51 APOA1 APOB
22 phosphatidylinositol 3-kinase signaling GO:0014065 9.5 EDN1 IRS1 PIK3C2A
23 negative regulation of hydrolase activity GO:0051346 9.48 APOA1 NOS3
24 lipoprotein biosynthetic process GO:0042158 9.46 APOA1 APOB
25 regulation of systemic arterial blood pressure by endothelin GO:0003100 9.43 EDN1 NOS3
26 triglyceride catabolic process GO:0019433 9.43 APOA1 APOB FABP3
27 regulation of blood pressure GO:0008217 9.35 ACE EDN1 NOS3 NPPA NPPB
28 negative regulation of blood coagulation GO:0030195 9.33 EDN1 KNG1 SERPINE1
29 regulation of blood vessel size GO:0050880 9.02 EDN1 KNG1 NOS3 NPPA NPPB

Molecular functions related to Coronary Artery Anomaly according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 phospholipid binding GO:0005543 9.43 APOA1 APOB PON1
2 hormone activity GO:0005179 9.33 EDN1 NPPA NPPB
3 signaling receptor binding GO:0005102 9.17 EDN1 GJA1 KNG1 NPPA NPPB PLAT
4 hormone receptor binding GO:0051427 8.96 NPPA NPPB

Sources for Coronary Artery Anomaly

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....